Open AccessS201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN AN OPEN‐LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)
Author(s) -
CarloStella C.,
Ansell S.,
Zinzani P. L,
Radford J.,
Maddocks K.,
Pinto A.,
Collins G. P.,
Bachanova V.,
Bartlett N.,
BenceBruckler I.,
Hamadani M.,
Kline J.,
Mayer J.,
Savage K. J.,
Advani R.,
Caimi P.,
Casasnovas R.O.,
Feldman T.,
Hess B.,
BastosOreiro M.,
Iyengar S.,
Eisen S.,
Negievich Y.,
Wang L.,
Wuerthner J.,
Herrera A. F.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843696.37630.1c
Subject(s) - medicine , brentuximab vedotin , population , adverse effect , phases of clinical research , clinical endpoint , refractory (planetary science) , gastroenterology , oncology , clinical trial , lymphoma , surgery , hodgkin lymphoma , physics , environmental health , astrobiology